Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1

Michael K. Racke, Suhayl Dhib-Jalbut, Barbara Cannella, Paul S. Albert, Cedric S. Raine, Dale E. McFarlin

Research output: Contribution to journalArticle

333 Citations (Scopus)

Abstract

Experimental allergic encephalomyelitis (EAE) is an autoimmune disease characterized by inflammation and demyelination in the central nervous system. The effect of the immunosuppressive molecule transforming growth factor-β, (TGF-β1) on chronic relapsing EAE produced by the transfer of myelin basic protein-specific T cell lines was studied. TGF-β1 markedly inhibited the activation and proliferation of myelin-basic protein-specific lymph node cells in vitro. This reduced the capacity of these cells to transfer EAE. In addition, administration of TGF-β1 in vivo consistently resulted in an improved clinical course, even when given during ongoing disease. Immunopathologic study demonstrated a marked reduction in central nervous system damage and expression of cell-surface lymphocyte function-associated Ag-1 and class II MHC molecules in TGF-β1-treated mice. These findings have identified TGF-β1 as a possible therapeutic agent for the human demyelinating disease multiple sclerosis.

Original languageEnglish (US)
Pages (from-to)3012-3017
Number of pages6
JournalJournal of Immunology
Volume146
Issue number9
StatePublished - May 1 1991

Fingerprint

Autoimmune Experimental Encephalomyelitis
Transforming Growth Factors
Myelin Basic Protein
Demyelinating Diseases
Central Nervous System
Immunosuppressive Agents
Autoimmune Diseases
Multiple Sclerosis
Lymph Nodes
Lymphocytes
Inflammation
T-Lymphocytes
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Racke, M. K., Dhib-Jalbut, S., Cannella, B., Albert, P. S., Raine, C. S., & McFarlin, D. E. (1991). Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. Journal of Immunology, 146(9), 3012-3017.

Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. / Racke, Michael K.; Dhib-Jalbut, Suhayl; Cannella, Barbara; Albert, Paul S.; Raine, Cedric S.; McFarlin, Dale E.

In: Journal of Immunology, Vol. 146, No. 9, 01.05.1991, p. 3012-3017.

Research output: Contribution to journalArticle

Racke, MK, Dhib-Jalbut, S, Cannella, B, Albert, PS, Raine, CS & McFarlin, DE 1991, 'Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1', Journal of Immunology, vol. 146, no. 9, pp. 3012-3017.
Racke MK, Dhib-Jalbut S, Cannella B, Albert PS, Raine CS, McFarlin DE. Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. Journal of Immunology. 1991 May 1;146(9):3012-3017.
Racke, Michael K. ; Dhib-Jalbut, Suhayl ; Cannella, Barbara ; Albert, Paul S. ; Raine, Cedric S. ; McFarlin, Dale E. / Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1. In: Journal of Immunology. 1991 ; Vol. 146, No. 9. pp. 3012-3017.
@article{cec44a6ab77d42aaa6e3fbd3e445e3a1,
title = "Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1",
abstract = "Experimental allergic encephalomyelitis (EAE) is an autoimmune disease characterized by inflammation and demyelination in the central nervous system. The effect of the immunosuppressive molecule transforming growth factor-β, (TGF-β1) on chronic relapsing EAE produced by the transfer of myelin basic protein-specific T cell lines was studied. TGF-β1 markedly inhibited the activation and proliferation of myelin-basic protein-specific lymph node cells in vitro. This reduced the capacity of these cells to transfer EAE. In addition, administration of TGF-β1 in vivo consistently resulted in an improved clinical course, even when given during ongoing disease. Immunopathologic study demonstrated a marked reduction in central nervous system damage and expression of cell-surface lymphocyte function-associated Ag-1 and class II MHC molecules in TGF-β1-treated mice. These findings have identified TGF-β1 as a possible therapeutic agent for the human demyelinating disease multiple sclerosis.",
author = "Racke, {Michael K.} and Suhayl Dhib-Jalbut and Barbara Cannella and Albert, {Paul S.} and Raine, {Cedric S.} and McFarlin, {Dale E.}",
year = "1991",
month = "5",
day = "1",
language = "English (US)",
volume = "146",
pages = "3012--3017",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "9",

}

TY - JOUR

T1 - Prevention and treatment of chronic relapsing experimental allergic encephalomyelitis by transforming growth factor-β1

AU - Racke, Michael K.

AU - Dhib-Jalbut, Suhayl

AU - Cannella, Barbara

AU - Albert, Paul S.

AU - Raine, Cedric S.

AU - McFarlin, Dale E.

PY - 1991/5/1

Y1 - 1991/5/1

N2 - Experimental allergic encephalomyelitis (EAE) is an autoimmune disease characterized by inflammation and demyelination in the central nervous system. The effect of the immunosuppressive molecule transforming growth factor-β, (TGF-β1) on chronic relapsing EAE produced by the transfer of myelin basic protein-specific T cell lines was studied. TGF-β1 markedly inhibited the activation and proliferation of myelin-basic protein-specific lymph node cells in vitro. This reduced the capacity of these cells to transfer EAE. In addition, administration of TGF-β1 in vivo consistently resulted in an improved clinical course, even when given during ongoing disease. Immunopathologic study demonstrated a marked reduction in central nervous system damage and expression of cell-surface lymphocyte function-associated Ag-1 and class II MHC molecules in TGF-β1-treated mice. These findings have identified TGF-β1 as a possible therapeutic agent for the human demyelinating disease multiple sclerosis.

AB - Experimental allergic encephalomyelitis (EAE) is an autoimmune disease characterized by inflammation and demyelination in the central nervous system. The effect of the immunosuppressive molecule transforming growth factor-β, (TGF-β1) on chronic relapsing EAE produced by the transfer of myelin basic protein-specific T cell lines was studied. TGF-β1 markedly inhibited the activation and proliferation of myelin-basic protein-specific lymph node cells in vitro. This reduced the capacity of these cells to transfer EAE. In addition, administration of TGF-β1 in vivo consistently resulted in an improved clinical course, even when given during ongoing disease. Immunopathologic study demonstrated a marked reduction in central nervous system damage and expression of cell-surface lymphocyte function-associated Ag-1 and class II MHC molecules in TGF-β1-treated mice. These findings have identified TGF-β1 as a possible therapeutic agent for the human demyelinating disease multiple sclerosis.

UR - http://www.scopus.com/inward/record.url?scp=0025892475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025892475&partnerID=8YFLogxK

M3 - Article

VL - 146

SP - 3012

EP - 3017

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 9

ER -